Cargando…

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents

BACKGROUND: During two pivotal clinical trials of the infliximab biosimilar CT-P13 (PLANETAS and PLANETRA), antidrug antibodies (ADAs) and neutralising antibodies (NAbs) were detected in the sera of patients treated with CT-P13 and the reference product (RP; Remicade). OBJECTIVE: The aim was to asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reinisch, Walter, Jahnsen, Jørgen, Schreiber, Stefan, Danese, Silvio, Panés, Julián, Balsa, Alejandro, Park, Won, Kim, JiSoo, Lee, Jee Un, Yoo, Dae Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443869/ https://www.ncbi.nlm.nih.gov/pubmed/28497221 http://dx.doi.org/10.1007/s40259-017-0219-4

Ejemplares similares

Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection
por: Eser, Alexander, et al.
Publicado: (2020)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Remicade(®) (infliximab): 20 years of contributions to science and medicine
por: Melsheimer, Richard, et al.
Publicado: (2019)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects
por: Shin, Donghoon, et al.
Publicado: (2015)

Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
por: Ehrenpreis, Eli D.
Publicado: (2017)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
por: Tanaka, Y, et al.
Publicado: (2010)

The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review
por: Nahra, Vicky, et al.
Publicado: (2020)

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade(®))
por: Kim, Soohyun, et al.
Publicado: (2020)

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2022)

Twenty Years of Quiescence after Nonstop Remicade(®) (Infliximab) Infusions in a Child with Ocular Behçet Disease Presenting as Hypopyon-Anterior Uveitis Refractory to Immunosuppressants
por: Evereklioglu, Cem
Publicado: (2023)

The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate
por: Mojtahed Poor, Sorwe, et al.
Publicado: (2023)

The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
por: Magro, F., et al.
Publicado: (2018)

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017)

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies
por: Bitoun, Samuel, et al.
Publicado: (2023)

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques
por: Fang, Jing, et al.
Publicado: (2016)

The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017)

Antidrug resistance in the Indian ambient waters of Ahmedabad during the COVID-19 pandemic
por: Kumar, Manish, et al.
Publicado: (2021)

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017)

Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade(®) to Remsima(®)? An Observational Study
por: Xue, Laixi, et al.
Publicado: (2020)

Therapeutic Protein PEPylation: The Helix of Nonfouling Synthetic Polypeptides Minimizes Antidrug Antibody Generation
por: Hou, Yingqin, et al.
Publicado: (2019)

Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera
por: Beeg, Marten, et al.
Publicado: (2021)

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
por: Benucci, Maurizio, et al.
Publicado: (2018)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays
por: Rocha, Cátia, et al.
Publicado: (2020)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade(®)
por: Melsheimer, Richard, et al.
Publicado: (2018)

Importance of Emotional Competence in Designing an Antidrug Education Curriculum for Junior Secondary School Students in Hong Kong
por: Law, Ben M. F., et al.
Publicado: (2011)

Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision
por: Adair, Patrick R., et al.
Publicado: (2017)

Impact of glycoengineering and antidrug antibodies on the anticancer activity of a plant‐made lectin‐Fc fusion protein
por: Dent, Matthew, et al.
Publicado: (2022)

Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove
por: Tsakok, Teresa, et al.
Publicado: (2023)

Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
por: Jukic, Tomislav, et al.
Publicado: (2023)

Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease
por: Smits, Lisa J. T., et al.
Publicado: (2017)

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
por: Kim, Chan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9mm0a1hj1c5cc55j46v2622r6q